AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 201 min read$TARS

ETFs Are Net Sellers of Tarsus Pharmaceuticals (TARS) on Oct. 16

ETFs were net buyers of Tarsus Pharmaceuticals (TARS) on Oct. 16, with $89.4 million in net inflows. FBT was the largest buyer, adding $90.7 million worth of shares. TARS has a market cap of $3.4 billion and reported $606.3 million in trailing 12-month revenue, up 90.9%. The stock is down 15.12% year to date.

Original reporting
finance.yahoo.com
Published Oct 20, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 11:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
ETFs Are Net Sellers of Tarsus Pharmaceuticals (TARS) on Oct. 16 — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$TARSBullishLow
01

Why it matters

ETF net buying may provide short‑term price support but lacks a fundamental catalyst.

02

Market read

ETF flow data offers a modest trading signal for TARS; broader market impact is minimal.

03

What to watch

No accompanying earnings or product news; flow may reflect portfolio rebalancing rather than conviction.

Relevance 6/10Novelty 5/10Timing: intraday on Oct 16

Background

The article reports daily ETF activity for Tarsus Pharmaceuticals, highlighting net buying versus selling across a set of funds.

Company-level read

Ticker impact

$TARSBullishMedium confidence
Context

ETF flows show a net $89.4 million purchase on Oct 16, indicating fresh buying pressure for Tarsus Pharmaceuticals.

Expected impact

likely modest upside as ETFs add shares

Evidence & confidence

Large net inflow from multiple ETFs can lift price, but the signal is limited to one day.

Market effects

Sector

Shows renewed investor interest in biotech ETFs, may benefit peers.

Regional

U.S. biotech sector sees modest inflow.

Global

Limited to U.S. market participants.

Counterpoint

What could challenge this read

ETF buying could be temporary and price may revert if fundamentals remain weak.

Key entities

  • company
    Tarsus Pharmaceuticals

    U.S. biotech firm developing eye‑care therapeutics.

  • ETF
    FBT

    Largest buyer, added 1.33 M shares worth $90.7 M.

Read at source← All news

Related articles

SEP 16
$TARSMed

TARS Reinstated by Barclays -- Rating Upgraded to Overweight

Barclays reinstated Tarsus Pharmaceuticals (TARS) with an Overweight rating and a $110.00 price target. The company's stock is currently trading at $78.23, with a GF Value™ of $160.86, indicating a 51.4% undervaluation. TARS has a GF Score™ of 46/100, reflecting mixed financial health and performance. The company focuses on biotechnology, particularly eye care, with its lead product being XDEMVY.

gurufocus.com2 min
SEP 10
$TARSHighAI 8/10

Tarsus Pharmaceuticals, Inc. (TARS): Completion of Acquisition or Disposition of Assets

Tarsus Pharmaceuticals, Inc. (TARS) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care September 4, 2026 Adds gildeuretinol (ALK-001), a differentiated Phase 3 oral investigational medicine designed to target the underlying biology of Stargardt’s disease, a pote

SEC EDGAR 8-K2 min
SEP 8
$TARSMed

Jefferies raises Tarsus Pharmaceuticals price target on guidance

Jefferies raised its price target on Tarsus Pharmaceuticals (NASDAQ:TARS) to $105, citing strong guidance and recent prescription data. The stock has surged 23% in the past week. Tarsus reported Q2 2026 sales of $173.9M, beating expectations, and raised full-year sales guidance for XDEMVY. The company has a market cap of approximately $4B and is considered undervalued by InvestingPro analysis.

investing.com2 min
SEP 4
$TARSMed

Tarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease Program

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a Phase 3 investigational therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is expected to report topline data in 2029. The acquisition expands Tarsus' pipeline and supports its eye care strategy. TARS shares closed at $83.21 on Thursday, up 0.54%.

rttnews.com2 min
SEP 4
$TARSMed

A potentially blinding eye disease has no FDA-approved therapy. Tarsus bought a company developing one.

Tarsus Pharmaceuticals (TARS) completed its acquisition of Alkeus Pharmaceuticals, gaining worldwide rights to ALK-001, a late-stage oral therapy for Stargardt disease. ALK-001 has received multiple FDA designations and is in a Phase 3 trial with topline data expected in 2029. Tarsus believes ALK-001 could be a blockbuster treatment for this inherited retinal disease with no FDA-approved therapies.

stocktitan.net2 min